Advances in Understanding the Role of Aloe Emodin and Targeted Drug Delivery Systems in Cancer

Cancer is one of the important causes of death worldwide. Despite remarkable improvements in cancer research in the past few decades, several cancer patients still cannot be cured owing to the development of drug resistance. Natural sources might have prominence as potential drug candidates. Among the several chemical classes of natural products, anthraquinones are characterized by their large structural variety, noticeable biological activity, and low toxicity. Aloe emodin, an anthraquinone derivative, is a natural compound found in the roots and rhizomes of many plants. This compound has proven its antineoplastic, anti-inflammatory, antiangiogenic, and antiproliferative potential as well as ability to prevent cancer metastasis and potential in reversing multidrug resistance of cancer cells. The anticancer property of aloe emodin, a broad-spectrum inhibitory agent of cancer cells, has been detailed in many biological pathways. In cancer cells, these molecular mechanisms consist of inhibition of cell growth and proliferation, cell cycle arrest deterioration, initiation of apoptosis, antimetastasis, and antiangiogenic effect. In accordance with the strategy of developing potential drug candidates from natural products, aloe emodin's low bioavailability has been tried to be overcome by structural modifications and nanocarrier systems. Consequently, this review summarizes the antiproliferative and anticarcinogenic properties of aloe emodin, as well as the enhanced activity of its derivatives and the advantages of drug delivery systems on bioavailability

Cardiac functions and pericardial thickness changes in familial Mediterranean fever patients

Abstract Background The goal of the study is to ascertain how the pericardium and heart functions alter in patients with familial Mediterranean fever (FMF) both during the acute phase and the period of subclinical inflammation. Methods During the study, 99 patients diagnosed with FMF (35 of whom were in an FMF attack period) were recruited to this study, and 24 completely healthy children in the same age group—who did not have FMF and had not any cardiac condition that applied to visit the pediatric cardiology outpatient clinic for routine follow-up—were included as the control group. Results In patients with FMF, there was no discernible relationship between genetic abnormalities and pericardial thickness (p > 0.05). A significant difference was not observed in the diastolic and systolic cardiac function values between the control group and the FMF patients, with the exception of the parameters related to ejection time (ET), contraction time (IVCT), and relaxation time (IVRT). It was observed that pericardial thickness was greater in FMF patients than in study participants who did not have FMF, and this difference is statistically significant (p < 0.05). Conclusions It was determined that the effects of cardiac inflammation continued in children with FMF, even if they were asymptomatic. Therefore, it should be part of the follow-ups. Key points • In our study, cardiac functions and pericardial thickening of 99 FMF patients with and without attack were prospectively investigated. • In ongoing follow-up of patients with FMF, we found that inflammation, which affects all serosas, also affects the pericardium during the attract and nonattack phase. • We believe that cardiac functions, including the status of the pericardium, should be monitored as part of the long-term follow-up of FMF